Randomised clinical trial: Delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND i and II combined analysis

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2011, Pages 672-678

  Lichtenstein, G R ^a   Ramsey, D ^b   Rubin, D T ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASACOL 800; ASACOL HD; IMMUNOMODULATING AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COLONOSCOPY; DELAYED RELEASE FORMULATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; WOUND HEALING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLONOSCOPY; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MESALAMINE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 79951671131     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04575.x     Document Type: Article

References (26)

1. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85. (Pubitemid 39062279)
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 8; 353: 2462-76. (Pubitemid 41770166)
3. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75. (Pubitemid 46108735)
4. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
5. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8g/day (800mg tablets) compared with 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21: 827-34. (Pubitemid 351255702)
6. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8g/day (800mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-43.
7. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26: 205-15. (Pubitemid 46985493)
8. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10. (Pubitemid 19057603)
9. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM,. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8. (Pubitemid 40732094)
10. Irvine EJ,. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2007; 13: 1-11.
11. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohns Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96. (Pubitemid 24041204)
12. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802. (Pubitemid 46496629)
13. Han SW, McColl E, Steen N, Barton JR, Welfare MR,. The Inflammatory Bowel Disease Questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England. Scand J Gastroenterol 1998; 33: 961-6. (Pubitemid 28439314)
14. Rutter MD, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9. (Pubitemid 38182302)
15. Rubin DT,. The changing face of colorectal cancer in inflammatory bowel disease: progress at last. Gastroenterology 2006; 130: 1350-2.
16. Bansal R, Itzkowitz S, Harpaz H, et al. Severity of inflammation predicts progression to colorectal neoplasia in ulcerative colitis. Am J Gastroenterol 2005; 100: S-289 [Abstract #778].
17. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20. (Pubitemid 32061864)
18. Froslie KF, Jahnsen J, Mourn BA, et al. Mucosal healing in inflammatory bowel disease results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
19. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
20. Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-7. (Pubitemid 12120288)
21. Binder V,. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 1970; 5: 627-32.
22. Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001; 121: 261-7. (Pubitemid 32729373)
23. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnestoa. Gastroenterology 2006; 130: 1039-46.
24. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-6. (Pubitemid 39556902)
25. Mahadevan U,. Mucosal healing in Crohns disease: what you see is what you get? Gastrointest Endosc 2006; 63: 443-4. (Pubitemid 43261470)
26. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338-46.